Vimentin is an intermediate filament protein traditionally considered to be an intracellular protein with a structural role. However, recent evidence suggests that vimentin can also be found outside the cell in disease conditions such as cancer, traumatic tissue injury, and inflammation. Extracellular vimentin was previously found to stimulate innate immunity by increasing monocyte and macrophage ability to kill bacteria. However, vimentin has also been previously found to decrease neutrophil infiltration into inflamed tissue. How extracellular vimentin affects the initiation of adaptive immune responses is unknown. Initiation of adaptive immunity involves priming of naïve T cells by antigen-presenting cells, the most effective of which are dendritic cells (DCs). In this study, we demonstrate how extracellular vimentin modulates lipopolysaccharide (LPS) -induced activation of human DCs. Using cytometric bead arrays, we show that extracellular vimentin decreases LPS-activated DC secretion of pro-inflammatory cytokines IL-6 and IL-12 while increasing secretion of the antiinflammatory cytokine IL-10. Using flow cytometry, we show that extracellular vimentin does not significantly affect LPS-induced DC surface expression of MHC I (HLA-ABC) or MHC II (HLA-DR) presentation molecules, costimulatory factors (CD80, CD86), or the DC maturation marker (CD83). Further, LPS-stimulated DCs cocultured with allogeneic naïve CD4 + T cells (Th0) induced less secretion of the pro-inflammatory Th1 effector cytokine IFN-γ in the presence of vimentin than in the presence of LPS alone. This result suggests that vimentin reduces Th1 differentiation. Taken together, our data suggest that extracellular vimentin may inhibit pro-inflammatory adaptive immune responses, by blocking DC secretion of pro-inflammatory cytokines. Thus, extracellular vimentin may play an important role in cancer or trauma-complications by inducing suppression of the adaptive immune response. In a positive sense, the presence of extracellular vimentin may prevent tissue-damage from contributing to the development of autoimmunity. Consequently, extracellular vimentin may become a novel drug target for treatment of a variety of pro-and anti-inflammatory disease conditions.
Introduction
Vimentin is an intermediate filament protein normally found within the cells of many tissues, where it maintains cellular integrity, helps the cell resist mechanical stress (Ivaska et al., 2007) , and positions cell organelles (Perez-Sala et al., 2015) . However, there is also evidence of extracellular or cell surface vimentin presence in a variety of diseases including: liver cancer (Sun et al., 2010) , colon cancer (Bukhari et al., 2015) , liver disease (Carter and Howell, 2013; Lee et al., 2014) , organ transplant (Carter and Howell, 2013; Carter et al., 2005; Barber et al., 2004; Azimzadeh et al., 2005) , atherosclerosis (Thiagarajan et al., 2013) , myonecrosis (Bryant et al., 2006) , pulmonary fibrosis (Li et al., 2017) , and systemic lupus erythematosus (Alcover et al., 1984) . Several sources of extracellular or cell surface vimentin have been proposed. In pro-inflammatory environments, vimentin is released by macrophages (Mor-Vaknin et al., 2003) , monocytes (Thiagarajan et al., 2013) , neutrophils (Kaplan, 2013) , and hepatocytes (Lee et al., 2014) . In the presence of TGF-β, a cytokine with pro-and anti-inflammatory effects (Pickup et al., 2013) , vimentin is released by endothelial cells (Li et al., 2017) . In apoptotic lymphocytes (Boilard et al., 2003) and neutrophils (Moisan and Girard, 2006) , and in injured skeletal muscle cells (Bryant et al., 2006) , vimentin is localized to the cell surface. Generally, vimentin can also be released from cells in the event of overexpression (Sun et al., 2010) , traumatic cell injury, or cell death (Lee et al., 2014; Azimzadeh et al., 2005; Mellgren, 2010) . Additional reports indicate that vimentin can be secreted from cultured astrocytes (Greco et al., 2010) .
Extracellular vimentin has been proposed to function as a damage associated molecular pattern (DAMP), as it has immunostimulatory properties. For example, extracellular vimentin induces superoxide production in macrophages (Mor-Vaknin et al., 2003) and monocytes (Thiagarajan et al., 2013) , which increases the ability of these cells to kill bacteria (Mor-Vaknin et al., 2003) . Additionally, the presence of vimentin on the cell surface can induce NK cell-mediated lysis of the cell (Garg et al., 2006) . However, extracellular vimentin may also attenuate inflammation and promote tissue repair, as it decreases adhesion to platelets and activated endothelial cells in neutrophils (Lam et al., 2018) , and promotes axonal growth in neurons (Shigyo et al., 2015) . However, very little is known about the effects of extracellular vimentin on adaptive immunity.
In the present study, we demonstrate the effects of extracellular vimentin on dendritic cells (DCs), the most effective antigen-presenting cells in the body. DCs play an important role in priming naïve T cells, and thus are key to initiating an adaptive immune response (Mellman and Steinman, 2001 ). DC-mediated CD4+T cell activation and differentiation is thought to be mediated by three signals: 1) peptide loading onto an MHC II molecule, 2) surface expression of co-stimulatory molecules, and 3) secretion of pro-or anti-inflammatory cytokines. The first two signals are required for T cell activation, while the cytokines influence what type of CD4 + T cell (pro-or anti-inflammatory) arises from naïve CD4 + T cells. Because DCs are found at low frequencies in human peripheral blood (< 1% of peripheral blood leukocytes (Dillon et al., 2011; Ueda et al., 2003; Ciaramella et al., 2016) ), a common and convenient model for the human DC is the monocyte-derived DC (moDC), which is the specific DC model used in this study.
Materials and methods

Isolation and culture of monocyte-derived dendritic cells from human peripheral blood
Monocyte-derived dendritic cells (moDCs) were prepared from freshly collected human peripheral blood cells from aphaeresis filter cones donated by the LifeStream blood bank (San Bernardino, CA). To deplete the red blood cells, the blood was incubated with an ammonium chloride solution for 15 min, centrifuged, and then the supernatant was removed (Mbongue et al., 2015) . This red blood cell depletion process was then repeated one more time to yield a leukocyte mixture. The CD14+ monocytes were isolated from the leukocyte mixture using magnetic CD14 microbeads human as described by the manufacturer (Miltenyi Biotech, CA; . Briefly, CD14+ monocyte isolation involved: incubation of the leukocytes with anti-CD14 antibodies bound to magnetic beads for 15 min at 4°C in the dark, followed by separation of the CD14+ cells from all other leukocytes by binding the beads to a magnetic LS column (Miltenyi Biotech) in a magnet (MidiMacs separator, Miltenyi Biotech). The CD14+ monocytes were seeded (10^6 cells/mL) in 24-well (0.5 mL/well) or 96-well (0.2 mL/well) flat-bottom non-pyrogenic polystyrene tissue culture plates in moDC culture medium: RPMI 1640 medium (Mediatech Inc., VA) supplemented with 10% FBS (Atlanta Biologicals, GA), 100 U/mL penicillin-streptomycin (ThermoFisher, MA), 50 ng/ml human recombinant GM-CSF (Peprotech, NJ), and 10 ng/ml human recombinant IL-4 (Peprotech). The monocyte cell culture was fed at 2-day intervals by gentle replacement of 50% of the medium with pre-warmed fresh culture medium. The monocytes were cultured for 6 days to allow their differentiation into moDCs, prior to treatment of the moDCs with vimentin, lipopolysaccharide (LPS), and polyinosinic-polycytidylic acid (poly I:C). For vimentin, LPS, and poly I:C concentrations, see Section 2.3.
Isolation of naïve CD4 + T cells from human peripheral blood
Leukocytes were isolated from aphaeresis filter cones as described in Section 2.1. The naïve CD4 + T cell fraction was isolated from the leukocyte mixture by negative selection using Naïve CD4 + T cell Isolation Kit II human as described by the manufacturer (Miltenyi Biotech, catalog #130-094-131). Briefly, isolation involved: initial incubation of the leukocytes with Biotin-Antibody Cocktail for 5 min at 4°C in the dark, followed by incubation with Microbead Cocktail for 10 min, and passage through a LS column in a magnet. The untouched, naïve CD4 + T cells were resuspended in R10 culture medium: RPMI 1640 medium supplemented with 10% FBS and 100 U/mL penicillin-streptomycin. See Section 2.3 for final cell concentrations.
Cell treatment conditions
Vimentin protein (Sino Biological, China) was solubilized in PBS (phosphate buffered saline, pH 7.4) at 0.25 mg/mL.
For moDC monoculture, moDCs (10^6 cells/mL) were incubated with vimentin (10 ug/mL), LPS (10 ng/mL) +/− vimentin, or poly I:C (10 ug/mL) +/− vimentin in moDC culture medium (see Section 2.1) for 48 h at 37°C in the presence of 5% CO 2 .
For moDC:T cell co-culture: moDCs (1 × 10^4 cells/well) were plated in R10 culture medium in 96-well tissue culture plates, and then treated. After the moDCs had been treated for 8 to 10 h, naïve CD4 + T cells (0.8-1.0 × 10^5 cells/well) were added to the moDCs. The coculture treatment groups included: untreated, vimentin (10 ug/mL), and LPS (20 ng/mL) +/− vimentin. The naïve CD4 + T cell monoculture treatment groups were the same as the co-culture treatment groups. The co-cultures and naïve CD4 + T cell monocultures were incubated for an additional 4 days at 37°C in the presence of 5% CO 2 .
Surface staining and flow cytometry
For the purpose of staining cells in preparation for flow cytometry, washing is: addition of 200 u L of PBS, centrifugation (524×g, 5 min, 4°C), and removal of supernatant. Working solution of Fixable Viability Dye eFluor 450 (eBioscience, CA) is a 1:1000 dilution in PBS.
After treatment, the cells were incubated with 50 u L of working solution of Fixable Viability Dye eFluor 450 for 30 min at 4°C in the dark to distinguish between living (FVD450-) and dead (FVD450+) cells. The moDCs were subsequently washed once with PBS, resuspended in PBS (10 u L), and incubated with conjugated antibodies (indicated below) for 15 min at 4°C in the dark. The cells were washed with PBS and fixed with 1% paraformaldehyde solution before flow cytometric analysis using the MACSQuant Analyzer (Miltenyi Biotech).
The following anti-human antibodies were used to stain moDC monocultures: CD14 PerCP (clone HCD14), CD11c PE-Cy7 (clone 3.9), Fig. 1 . Vimentin does not activate moDCs. The moDCs were treated with vehicle (PBS), vimentin, or LPS, or were untreated, for 48 h. A and B. Expression of cell surface markers on moDCs analyzed by flow cytometry. A. Sequential gating strategy: single cells were selected based on forward scatter area and height, then intact cells were selected based on forward and side scatter, then living cells were selected based on detection of viability dye (FVD450), and then moDCs were selected based on detection of CD14 and CD11c B. Expression of cell surface markers on moDCs, analyzed by flow cytometry. The representative histograms show surface staining of HLA ABC, HLA DR, CD80, CD86, and CD83 in the gated moDCs. Data are shown from one representative donor out of three analyzed C, D, and E. Concentrations of IL-6, IL-10, IL-12, TGF-β, and IL-1β were detected by ELISA. n = 6 healthy blood donors. C is actual concentrations. D is actual concentrations of IL6, IL10, and IL12 but with the LPS group removed to facilitate comparisons between the other treatment groups. E is relative expression. Each black dot is one donor's cells in one treatment group. Gray bars are medians.
Fig. 2. Effect of vimentin on LPS-induced moDC activation.
The moDCs were treated with LPS +/-vimentin, or were untreated, for 48 h. Unless otherwise stated, the vimentin concentration was 10 ug/mL. A. Expression of cell surface markers on moDCs analyzed by flow cytometry. The representative histograms show surface staining of HLA ABC, HLA DR, CD80, CD86, and CD83 in the gated live moDCs. Data are shown from one representative donor out of three analyzed. B and C. Concentrations of IL-6, IL-10, and IL-12 in the cell culture supernatant were assessed by CBA. Concentrations of TGF-β1 and IL-1β were assessed by ELISA. n = 6 to 7 healthy blood donors. B is actual concentrations. C is relative expression. Each black dot is one donor's cells in one treatment group. Gray bars are medians. * P < 0.05 for comparison between LPS and LPS + vim. D. Effect of different concentrations (0, 0.4, 2, or 10 ug/mL) of extracellular vimentin on LPS-induced. IL-12 secretion, as detected by CBA. n = 4 healthy blood donors. Each black dot is one donor's cells in one treatment group. Gray bars are medians.
CD80 FITC (clone 2D10), CD86 PE (clone IT2.2), CD83 APC (clone HB15e) (all from Biolegend, CA); HLA-ABC FITC (clone G46-2.6) and HLA-DR FITC (clone L243) (both from BD Biosciences). The following isotype control antibodies were used: mouse IgG1-FITC, IgG2b-PE, IgG2-PerCP, IgG1-PE-Cy7, IgG1-APC (all from Biolegend).
The following anti-human antibodies were used to stain moDC:T cell co-cultures and T cell monocultures: CD3 FITC (clone HIT3a), CD25 APC (clone BC96, both from Biolegend); CD45RO PE (clone UCHL1, BD Fig. 3 . Effect of vimentin on naïve CD4 + T cell activation in moDC:T cell co-cultures. Co-cultures of moDCs and naïve CD4 + T cells were treated for 4 days. A and B. Supernatant was harvested. Cytokine concentrations were assessed by CBA. A is actual concentrations. B is relative expression. Each black dot is one donor's cells in one treatment group. Gray bars are means. * P < 0.05 for comparison between LPS and LPS + vim. C. We assessed expression of activation marker CD25 and memory marker CD45RO by flow cytometry. Plots are gated on live T cells (CD3+ FVD450-lymphocytes). Representative data are from 1 out of 3 independent experiments. D and E. Naïve CD4 + T cells were stained with CellTrace Far Red. These naïve CD4 + T cells were co-cultured with treated moDCs for 4 days. D. Dot plots are gated on live CD4 + T cells (CD4+ FVD450-lymphocytes). Representative data are from 1 out of 4 independent experiments. E. Bar graph indicates frequency of CD4 + T cells that have proliferated at least once. This contains data from 4 moDC donors, as well as a T cell monoculture control. biosciences).
Singly-stained compensation beads (eBioscience) and a 1:1 mixture of live and heat-killed cells stained with Fixable Viability Dye eFluor 450 were used to establish compensation settings. Flow cytometry data analysis was performed using Flowjo data analysis software (FlowJo, OR).
Proliferation assay
Working solution of CellTrace Far Red is a 1:1000 dilution of CellTrace Far Red DMSO stock solution (1 mM) in pre-warmed PBS. Working solution was prepared immediately prior to use.
Isolated T cells were incubated with CellTrace Far Red working solution (10^6 cells/mL staining solution) for 20 min at 37°C in the dark. To remove free dye, R10 medium (5 × staining solution volume) was then added to the cells for an additional 5 min. The cell solution was centrifuged (524×g, 5 min, 4°C) and the supernatant was removed. The remaining pellet was resuspended in pre-warmed R10 medium. The stained T cells were then cultured for 4 days as stated in Section 2.3. As described in Section 2.4, the cells were stained for viability and for surface markers, and analyzed via flow cytometry, with the following two modifications: The only antibodies used for surface staining were CD3 FITC (clone HIT3a) and CD4 PerCP-Cy5.5 (clone RPA-T4) (both from Biolegend). A 1:1 mixture of unstained T cells and CellTrace Far Red stained T cells was used to establish compensation settings.
Cytokine cytometric bead array
MoDC culture supernatant was harvested after 48 h of treatment. MoDC:T cell co-culture and T cell culture supernatant was harvested after 96 h of treatment. Cytokine concentrations in the moDC culture supernatant were assessed with cytometric bead array (CBA) flex sets for IL-6, IL-10, IL-12 as described by the manufacturer (BD Biosciences) on a MacsQuant flow cytometer. Similarly, cytokine concentrations in the co-culture and T cell culture supernatant were assessed with CBA flex sets for IL-17 and IFN-γ. Data analysis was performed with FlowJo data analysis software. Protein concentrations were calculated from median fluorescence intensity. Relative expression is concentration of sample/concentration of sample treated with LPS alone.
ELISA
MoDC culture supernatant was harvested after 48 h of treatment. Cytokine concentrations in the culture supernatant were assessed with Uncoated ELISA kits for IL-1β, IL-6, IL-10, IL-12, and TGF-β1 as described by the manufacturer (ThermoFisher). For TGF-β1, this procedure involves acid activation and neutralization. Relative expression is concentration of cytokine in the sample/concentration of cytokine in the sample treated with LPS alone.
Statistical analysis
Unless otherwise specified, student's paired t-test was used to compare results from samples incubated with and without vimentin. Due to observed non-normality in cytokine expression levels in the DC monocultures, Wilcoxon signed rank test was used to compare cytokine expression levels from DC monocultures incubated with and without vimentin. P value less than 0.05 was considered significant.
Results
Immature moDCs
It is unknown whether vimentin alone can induce activation of DCs. We performed monoculture experiments to assess the effect of vimentin on immature moDCs. The moDCs were treated with or without vimentin. No robust differences were found in the surface expression levels of the following activation-associated surface markers: MHC I protein HLA-ABC, MHC II protein HLA-DR, costimulatory factors CD80 and CD86, and maturation marker CD83 (Fig. 1A, B) . In addition, no significant changes were found in the secretion of the cytokines IL-6, IL-10 or TGF-β1. IL-12 was undetectable or very low in all samples treated with nothing, vehicle, or vimentin alone (Fig. 1C, D, E) . Similarly, IL-1β was undetectable in all samples treated with nothing, vehicle, or vimentin alone. The lack of significant differences suggests that vimentin alone does not activate DCs in most humans.
Addition of vimentin does not affect LPS-induced moDC expression of activation-associated surface markers
The effect of extracellular vimentin on DC activation is unknown. Therefore, we assessed whether extracellular vimentin could alter LPS- induced activation in moDCs. The moDCs were stimulated with LPS, in the absence or presence of extracellular vimentin. To determine whether vimentin alters LPS-induced moDC activation, we used flow cytometry to measure the surface expression of surface markers associated with moDC activation. These markers are MHC I protein HLA-ABC, MHC II protein HLA-DR, costimulatory factors CD80 and CD86, and the DC maturation marker CD83. All of these proteins were verified to be highly expressed in moDCs activated with LPS. The addition of MFI of CD86 PE in samples from 6 donors. C. Concentrations of IL6, IL10, and IL12 were detected by ELISA. Gray bars are medians. n = 6 healthy blood donors.
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vimentin had no significant effect on the LPS-induced high level of surface expression of any of these proteins ( Fig. 2A) .
Addition of vimentin changes LPS-induced moDC cytokine secretion
Another aspect of DC activation is cytokine secretion. Thus, we also assessed whether extracellular vimentin could alter LPS-induced cytokine secretion in moDCs. MoDCs were stimulated with LPS, in the absence or presence of extracellular vimentin. CBA was used to assess the effects of vimentin on LPS-induced moDC production of IL-6, IL-10, and IL-12; ELISA was used to assess IL-1β and TGF-β1. In untreated moDCs, IL-10 and IL-12 concentrations were very low or undetectable by CBA, and IL-6 concentrations were < 5% of the value with LPS. LPS induced IL-6, IL-10, and IL-12 secretion. The moDCs also exposed to vimentin demonstrated a decrease in the LPS-induced secretion of IL-6 and IL-12 (Fig. 2B, C, D) , cytokines known to be associated with the ability of moDCs to promote differentiation of Th17 cells (Dienz and Rincon, 2009; Zhu et al., 2010) and Th1 cells (Zhu et al., 2010) , respectively. Interestingly, moDCs treated with vimentin also demonstrated increased secretion of IL-10, a powerful anti-inflammatory cytokine that limits the differentiation, proliferation, and cytokine production of Th1, Th2, and Th17 cells (Ng et al., 2013; Hawrylowicz and O'Garra, 2005) . However, there was no change in the secretion of total TGF-β1, another anti-inflammatory cytokine. Additionally, IL-1β was undetectable in both moDCs treated with LPS and with LPS + vimentin. The inability of LPS alone to induce IL-1β secretion from DCs is consistent with literature (Ainscough et al., 2014) .
MoDC:T cell co-culture
To address if extracellular vimentin alters moDC-mediated differentiation of T cells, moDCs were cultured with allogeneic naïve CD4 + T cells in the presence of LPS, with and without extracellular vimentin. The presence of LPS induces IFN-γ secretion, which is consistent with Th1 differentiation. However, the addition of vimentin decreases the amount of LPS-induced IFN-γ secretion, suggesting a decrease in Th1 differentiation. (Fig. 3A, B) . Neither LPS nor LPS + vimentin treatment resulted in significant IL-17 secretion, as IL-17 was undetectable by CBA in most co-cultures (4/5 independent experiments).
The addition of vimentin to LPS did not affect the proportion of T cells that became activated T cells (CD25+) or memory T cells (CD45RO+), as indicated by surface markers assessed by flow cytometry (Fig. 3C) . As a control, co-cultures were also performed without treatment, or with the addition of vimentin alone. Vimentin alone did not alter the proportion of T cells that became effector T cells or memory T cells.
Another aspect of naïve T cell activation is proliferation, which was assessed by staining with a cell trace dye and detecting the dye with flow cytometry. LPS did increase moDC-mediated proliferation of allogeneic naïve CD4 + T cells. The addition of vimentin to LPS did not consistently impact this LPS-induced naïve CD4 + T cell proliferation (Fig. 3D, E) .
We also assessed the effects of extracellular vimentin on naïve CD4 + T cells, independent of DCs. IFN-γ and IL-17 secretion were undetectable in naïve CD4 + T cells treated with nothing, vimentin, LPS, or LPS + vimentin. Additionally, activated T cells (CD25+) and memory T cells (CD45RO+) were rare or undetectable in naïve CD4 + T cells treated with nothing, vimentin, LPS, or LPS + vimentin (Fig. 4) .
Addition of vimentin and poly I:C-induced moDC expression of activation-associated surface markers and cytokine secretion
In addition to activation by bacterial compounds, DCs are also subject to activation by viral compounds. One way to simulate an immune reaction to viral infection is with poly I:C, an analog of doublestranded RNA. Thus, we also assessed whether extracellular vimentin altered poly I:C-induced activation in moDCs. As expected based on literature (Verdijk et al., 1999) , poly I:C increased surface expression of HLA ABC, HLA DR, CD80, CD86, and CD83. The addition of vimentin decreased poly I:C-induced surface expression of CD86 (Fig. 5A, B) . The addition of vimentin had no robust effect on HLA ABC, HLA DR, CD80, or CD83. Poly I:C induced secretion of IL-6 and IL-10, but the addition of vimentin had no consistent effect on poly I:C-induced secretion of IL-6 or IL-10 (Fig. 5C ). Poly I:C did not induce secretion of IL-12 in most cases (5/6), and poly I:C + vimentin also did not induce secretion of IL-12 in most cases (5/6).
Discussion
Extracellular vimentin has been previously shown to change the behavior of monocytes, macrophages (Thiagarajan et al., 2013; MorVaknin et al., 2003) , and neutrophils (Lam et al., 2018) . Here, we have explored the effects of vimentin on DCs, the most effective antigen presenting cells. DCs recognize PAMPs and DAMPs, which enables them Fig. 6 . Proposed alteration of the immune response by extracellular vimentin. Extracellular vimentin can result from cancer, trauma, or inflammation. Extracellular vimentin increases the oxidative burst in monocytes and macrophages, thus increasing bactericidal activity (Thiagarajan et al., 2013; Mor-Vaknin et al., 2003) but possibly also inducing apoptosis in monocytes shortly afterwards (Ponath and Kaina, 2017) . Extracellular vimentin also decreases the infiltration of neutrophils into inflamed tissues (Lam et al., 2018) . In DCs, extracellular vimentin decreases the secretion of IL-12 and IL-6 while increasing IL-10 secretion. As a result, the DCs have decreased ability to stimulate the differentiation of naïve CD4 + T cells into Th1 cells. These opposing effects may have an advantageous effect as bacteria will be killed, further tissue damage will be prevented, and autoimmunity will be less likely. Potential disadvantages may include a decreased pro-inflammatory Th1 response against pathogens and cancer. However, there may be many other, unexplored effects of vimentin on immune cells.
M.B. Yu et al. Molecular Immunology 104 (2018) 37-46 to direct activation of the adaptive immune system by inducing the differentiation of antigen-specific naïve T cells into effector T cells. The resulting effector T cells can be either pro-or anti-inflammatory (Gi et al., 2009 ). In moDCs, vimentin does not appear to alter the LPSinduced surface expression of MHC I molecules, MHC II molecules, costimulatory molecules, or a marker of DC maturation (Fig. 2) . However, exposure to vimentin does shift LPS-induced cytokine production away from pro-inflammatory cytokines, in ways suggestive of a decreased ability to differentiate naïve CD4 + T cells (Th0) into Th1 cells, which are pro-inflammatory (Fig. 2) . We also observed that extracellular vimentin decreased LPS-induced moDC-mediated naïve CD4 + T cell differentiation into Th1 effector T cells (Fig. 3) . Our work could have broader implications for human health if vimentin also modulated DC activation induced by other stimuli from other pathogens. Thus, we assessed whether vimentin altered activation induced by poly I:C, known to simulate an immune response to viral infection through toll-like receptor 3 signaling (Verdijk et al., 1999; Nicodemus and Berek, 2010) . While there were no robust changes in DC cytokine secretion, vimentin did decrease the surface levels of costimulatory factor CD86, which suggests decreased activation of the DCs (Fig. 5) .
A previous study by Carter et al. (Carter and Howell, 2013) demonstrated that exposure of phytohaemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs) to vimentin decreases the secretion of pro-inflammatory cytokines secreted predominately by Th1 cells (Carter and Howell, 2013) . This observation suggests that exposure to extracellular vimentin decreases Th1 cell activation, a concept consistent with the data presented here. It is possible that the effects of vimentin identified in Carter et al.'s work were partially mediated by mature DCs present in the PBMC sample. While Carter et al. used a stimulus specific for T cells, it is also known that stimulated T cells can induce DC maturation (Miro et al., 2006; Asadi et al., 2012) . Exposure of unstimulated PBMCs to vimentin had no effect on Th1 cytokines (Carter and Howell, 2013) . In a study by Li et al. (2017) , in vitro exposure of unstimulated PBMCs to extracellular vimentin did not alter the proportion of Th1 cells in healthy volunteers. Our experimental protocol involving T cells is different from that of Li et al. (2017) in that we use moDCs and naïve CD4+T cells only, and we stimulate the moDCs with LPS. As suggested by Carter et al.'s work (Carter and Howell, 2013) , it is possible that extracellular vimentin has different effects depending on context. Extracellular vimentin could result from tissue damage or immune activation, which can lead to tissue damage. Perhaps the availability of extracellular vimentin could be a sign to the immune system that there is or will likely be tissue damage. Based on our experimental results, we suggest that exposure of maturing DCs to extracellular vimentin could be a molecular mechanism that shifts naïve T cell differentiation away from Th1 cells. This alteration in the DCs could help to arrest tissue damage as well as helping to prevent autoimmunity by inhibiting the differentiation into Th1 cells of naïve T cells that recognize self-antigens released by damaged tissues (Fig. 6) . Remaining pathogens could still be killed by monocytes or macrophages, as extracellular vimentin induces oxidative burst in these cells, and the oxidative burst is known to kill phagocytosed bacteria (Thiagarajan et al., 2013; Mor-Vaknin et al., 2003) . Additionally, there could be a transient decrease in monocytes, which may undergo apoptosis after an oxidative burst (Ponath and Kaina, 2017) . Such vimentin-induced pro-and anti-inflammatory effects could be beneficial in cases of mild injury or mild infection, by averting a major damaging pro-inflammatory immune response (Stoecklein et al., 2012; Islam et al., 2016) .
However, during severe injury or severe infection, the immunosuppressive effects of extracellular vimentin could be harmful because extracellular vimentin might contribute to increased risk of prolonged infection unresolvable without DC-mediated Th1 responses. It has been reported that severe injury or severe infection sometimes causes systemic inflammatory response syndrome (SIRS), in which the innate immune system becomes overactive while the adaptive immune system is suppressed (Stoecklein et al., 2012; Islam et al., 2016; Lord et al., 2014) . Therefore, the possibility exists that vimentin could be one of the molecules responsible for this potentially dangerous imbalance in the immune system. If this hypothesis is correct, decreasing the effects of vimentin on the immune system may be an attractive therapeutic strategy for increasing trauma patient survival, as immune-system-related complications are a significant cause of death after trauma (Sobrino and Shafi, 2013) .
In cancer, the tumor micro-environment is often immunosuppressive, which prevents the immune system from eliminating tumor cells (Kawakami et al., 2013; Vesely et al., 2011) . Vimentin was shown to be released constitutively by at least one cancer cell line (Sun et al., 2010) , suggesting the immunosuppressive mechanism of extracellular vimentin could be used by these cancer cells to facilitate evasion of pro-inflammatory immune responses. Given the subtlety of our results, we think that vimentin alone is unlikely to have a major immunosuppressive effect. However, it may function in conjunction with other immunosuppressive molecules upregulated in cancer cells such as indoleamine 2,3 dioxygenase (Uyttenhove et al., 2003) and TGF-β (Pickup et al., 2013) , to fine tune the immune response.
Future studies will explore the mechanism of extracellular vimentin's effect on moDCs, with a focus on how vimentin decreases LPSinduced IL-12 secretion. Literature reports indicate that vimentin interacts with the following cell surface receptors: dectin-1 (Thiagarajan et al., 2013) , insulin-like growth factor 1 receptor (IGF1R) (Shigyo et al., 2015) , NKp46 (Garg et al., 2006) , and P-selectin (Lam et al., 2018) . With the exception of P-selectin, all of these receptors are expressed in DCs (Su et al., 2004; Wang et al., 2006; Grunebach et al., 2002; Robbins et al., 2008) . Thus, there are at least three receptors that could be responsible for the effects of extracellular vimentin on DC activation. Since dectin-1 surface expression was shown to be high in mature DCs (Grunebach et al., 2002) , we believe that dectin-1 may be the most likely candidate. However, dectin-1 signaling is known to increase secretion of IL-6 and IL-12 in DCs (Goodridge et al., 2007) , and to promote Th17 responses (Loures et al., 2015) , which is not consistent with our data. Perhaps different dectin-1 ligands may generate different effects, as has been demonstrated for TLR4 (Piccinini et al., 2016) . Alternatively, IGF1R is also an attractive vimentin receptor candidate, as IGF1R signaling is known to increase IL-10 and decrease IL-6 secretion in DCs in the presence of LPS (Huang et al., 2015) , which is consistent with our data on the effects of extracellular vimentin.
Another area of interest for further studies is how DC activation is modulated by modified vimentin, such as citrullinated or carbamylated vimentin, both of which were shown to be important antigens in the pathogenesis of rheumatoid arthritis (Mastrangelo et al., 2015) .
Conclusion
Our experimental data suggest a novel role for vimentin in immune regulation. Extracellular vimentin was shown to affect the stimulatory properties of moDCs. We propose that extracellular vimentin is involved in several clinical scenarios including organ damage, autoimmunity, and cancer. Augmenting the effect of extracellular vimentin on DC activation may prevent or ameliorate autoimmunity and organ damage. Conversely, blocking vimentin's immunosuppressive effects may help to prevent chronic infection and the progression of cancer.
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